Tag Archives: monday lunch live

World Cancer Day special Monday Lunch Live – 4 Feb 2019

Patient-driven clinical trial offers new hope for rare cancer diagnosis

Marking World Cancer Day on 4 February, this special Monday Lunch Live event highlights new research into rare cancers – which collectively cause more cancer deaths in Australia than any single cancer type.

An innovative patient-driven clinical trial is exploring genomic profiling of rare cancers. The NOMINATOR trial is the result of a unique collaboration between a clinician-scientist and patient advocate. The trial investigates whether profiling can improve diagnosis and treatment of people with rare cancers.

Reflecting the I Am and I Will theme of World Cancer Day, Professor Clare Scott – clinician-scientist from the Walter and Eliza Hall Institute and medical oncologist at Peter MacCallum Cancer Centre; the Royal Women’s Hospital and Royal Melbourne Hospital – will be joined by Kate Vines, Founder and Head of Patient Care at Rare Cancers Australia. They will share their story of collaboration and commitment in developing the promising NOMINATOR trial.

Professor Clare Scott

Professor Clare Scott holds the Chair in Gynaecological Cancer at the University of Melbourne and is the Joint-Head of Clinical Translation and Laboratory Head at the Walter and Eliza Hall Institute and Medical Oncologist at the Peter MacCallum Cancer Centre, Royal Women’s and Royal Melbourne Hospitals.

She has 20 years’ experience in clinical cancer genetics, including working in Familial Cancer Clinics. Her clinical expertise is in gynaecological cancers and coordinating care for patients with rare cancers. Her laboratory focuses on drug resistance in ovarian cancer and other rare cancer subtypes, generating patient-specific models to understand and avert resistance to targeted therapeutics, in particular, PARP inhibitors.

Professor Scott chairs the COSA Rare Cancer group and has been awarded clinical fellowships from the Victorian Cancer Agency (2011, 2017), the Sir Edward Dunlop Cancer Research Fellow from the Cancer Council Victoria (2012) and the Jeannie Ferris Recognition Award in Gynaecological Cancer from Cancer Australia (2018).

Kate Vines

Kate Vines is the Founder and Head of Patient Care for Rare Cancers. In 2012 Kate and her husband Richard established Rare Cancers Australia, a patient advocacy group whose mission is to improve the lives and outcomes for rare cancer patients.

The event will also feature a patient experience perspective of the NOMINATOR trial.

Monday 4 February 2019

VCCC Building, Level 7 Lecture Theatres

Light lunch served from 12.30pm

Presentation from 1-2pm

Book now

Can’t join us in person? Join us online via our Webinar

The article is courtesy of our proud precinct partner, the Victorian Comprehensive Cancer Centre

Monday Lunch Live featuring A/Prof Allison Werner-Lin (US) – 10 December

Photograph of a Monday Lunch Live auditorium clapping and smiling

A/Prof Allison Werner-Lin is from the School of Social Policy and Practice, University of Pennsylvania. She is also senior advisor, US National Cancer Institute, Division of Cancer Epidemiology and Genetics and we are delighted to welcome her to the Victorian Comprehensive Cancer Centre.

Studying the ethical, legal, and social implications of genomic technologies is vitally important to identifying pathways towards greater engagement in personalised medicine, thereby extending the potential of genomic discovery. Yet, too often, psychosocial genomics research only includes individual perspectives and adaptations. When families are included, the focus is on the uptake of genetic testing by first-degree relatives and limited attention, if any, is given to other family members related by blood, law, or choice. Dr Werner-Lin’s research considers the ways families engage with genomic medicine and identifies how engagement is driven by ongoing family dynamics, social contexts, complex disease histories, and grief. Her work suggests practice models informed by family systems and developmental perspectives can support patient engagement in genomic medicine to reduce psychosocial harms.

Allison Werner-Lin’s research addresses the intersection of genomic discovery and family life. Her work seeks to broaden social work’s guiding ‘person-in-environment’ framework to include genetic variation as a core feature of assessment, one in constant interaction with developmental, sociocultural, and environmental contexts. Presently, her work addresses the ethical, legal, and social implications (ELSI) of emerging genomic technologies in reproductive, pediatric, adolescent, and young adult populations with inherited cancer predisposition syndromes.

She is among the first to explore the psychosocial challenges unique to women and men of reproductive age who carry a genetic mutation (BRCA1/2), which exposes carriers to elevated risk of hereditary breast and ovarian cancer. She holds appointments with the Clinical Genetics Branch of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute where she oversees psychosocial research addressing hereditary tumor predisposition syndromes, including Li-Fraumeni Syndrome. She is a member of the Scientific Committee governing the International Meeting on Psychosocial Aspects of Hereditary Cancer, serves on the Editorial Board of the Journal of Psychosocial Oncology, and is a Distinguished Fellow of the Society for Social Work and Research, where she serves as facilitator of the Cancer Special Interest Group, and the National Academies of Practice in Social Work.



Date: Monday 10 December 2018
Time: Presentation: 1-2pm
Venue: VCCC Building, Level 7 Lecture Theatres
Catering: Light lunch served from 12.30pm


Photograph of a Monday Lunch Live auditorium clapping and smiling